Part 1. LDTs: A Market Perspective

We have been discussing for some time in this blog the commonly held belief that biomarker testing is primarily being done using laboratory-developed tests as opposed to FDA-cleared and approved tests. There hasn’t yet been conducted, at least to our knowledge,...

Part 2. IVDs: A Market Perspective

In a previous post we looked at revenue growth for publicly-traded LDT developers, as the first step in attempting to better understand the market size and segmentation for LDTs. In this post we have pulled together some sales information for publicly-traded...

Post Mortem for Pathwork Diagnostics

Pathwork Dx Defunct; Future of Tissue of Origin Test Unclear from GenomeWeb Pathwork Diagnostics has gone out of business as of April 2. Here is the timeline: – Launched in 2006 when Predicant Biosciences merged with Pathwork Informatics and the merged entity,...

Myriad’s True Value

Some interesting points raised in a NY Times editorial yesterday regarding Myriad’s true underlying value being in its database of mutations. In a paper referenced by the editorial the authors describe Myriad’s database of BRCA1/2 mutations and the value...